RxDoctor Payments Data

Mary Anderson, MD

Family Medicine · Marshall, TXNPI 1083611057

Payments from drug & device makers

$5,046in general payments, 2019–2025

Across 301 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$718
  • AstraZeneca$459
  • GSK$290
  • Sunovion Pharmaceuticals Inc.$240
  • Boehringer Ingelheim$237
  • Otsuka America Pharmaceutical, Inc.$234
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$4,72694%
  • Education$3206%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,046 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$2,331
Medicare patients
104
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide365$431,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter192$185,387
EliquisApixaban159$156,745
OzempicSemaglutide133$154,944
Prolastin CAlpha-1-Proteinase Inhibitor12$111,447
JardianceEmpagliflozin97$89,676
TrulicityDulaglutide50$60,613
Breztri AerosphereBudesonide/Glycopyr/Formoterol76$53,705
KerendiaFinerenone37$50,488
RexultiBrexpiprazole32$50,004
Invega SustennaPaliperidone Palmitate13$47,610
MyrbetriqMirabegron62$44,171
LinzessLinaclotide37$43,699
FarxigaDapagliflozin Propanediol34$38,610
Victoza 3-PakLiraglutide34$27,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$124$492,571415 claims
GSKTrelegy Ellipta, Breo Ellipta$290$194,932207 claims
PfizerEliquis, Premarin$168$163,473171 claims
Novo NordiskOzempic$221$154,944133 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$237$117,041141 claims
Grifols USA, LLCProlastin C$112$111,44712 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$459$98,163129 claims
AbbVieLinzess, Vraylar$177$64,91252 claims
BayerKerendia$179$50,48837 claims
Otsuka America Pharmaceutical, Inc.Rexulti$234$50,00432 claims
MerckJanuvia, Belsomra, Steglujan$175$46,23555 claims
Astellas Pharma US IncMyrbetriq$718$44,17162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Marshall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →